- Organizations: Opus Genetics
Pipeline
Opus Genetics reports first-in-human trial data on LCA gene therapy
One-month findings from the first of three pediatric dosings indicate a clinically meaningful improvement in vision following just one dosing.
Pipeline
Opus Genetics receives Fast Track designation, reports phase 3 updates for phentolamine solution
VEGA-3 and LYNX-2 trials report completion and near completion of patient enrollment evaluating POS 0.75% for presbyopia and visual loss in low light conditions associated with keratorefractive surgery, respectively.
Pipeline
Opus Genetics and FDA agree on SPA for phase 3 NPDR gene therapy trial
Study’s newly-established primary endpoint will support a potential new drug application submission of APX3300 for market approval.
Business
Ocuphire Pharma just purchased Opus Genetics
Operating under the name “Opus Genetics,” the combined company features a pipeline of IRD-targeted gene therapy candidates.
Pipeline
FDA grants Opus Genetics Rare Pediatric Disease Designation for LCA gene therapy
Designation qualifies OPGx-LCA5 to receive a priority review voucher, if approved.
Research
Foundation Fighting Blindness grants Opus Genetics $1.7M to fund IRD programs
Project-based funding will support the advancement of two preclinical trials targeting retinitis pigmentosa.
Pipeline